A REVIEW ON RECEPTORS
Keywords:
receptors, enzyme & channel linked receptors, cholinergic, adnergic, dopamineAbstract
A molecule that binds to a receptor is called a ligand, and can be a peptide or another small molecule such as a neurotransmitter, hormone, pharmaceutical drug, toxin, or parts of the outside of a virus or microbe. Regardless of the nature of the initiating signal, the cellular responses are determined by the presence of receptors that specifically bind the signaling molecules. Binding of signal molecules causes a conformational change in the receptor, which then triggers the subsequent signaling cascade. A large number of these receptors have been identified and are grouped into three families defined by the mechanism used to transduce signal binding into a cellular response. Categories of cellular receptors: Membrane-impermeant signaling molecules can bind to and activate either channel linked receptors, enzyme linked receptors, or G protein coupled receptors. Membrane permeant signaling molecules activate intracellular. The cholinergic receptors includes muscarinic and nicotinic receptors and also adnergic, histaminic, prostanoid, dopamine, opiod, imidazoline receptors used in the various activity in the body.
Downloads
References
Arnt J, Hyttel J, Overo K (1984) Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol J Pharmacol Pharm 36:221–230
Baldessarini R, Marsh E (1990) Fluoxetine and side effects (letter). Arch Gen Psychiatry 47:191–192
Baron B, Ogden A, Siegel B, Stegeman J, Ursillo R, Dudley M (1988) Rapid downregulation of beta-adrenoceptors by coadministration of desipramine and fluoxetine. Eur J Pharmacol 154:125–134
Blaschko H (1974) The natural history of amine oxidases. Rev Physiol Biochem Pharmacol 70:83–148
Blier P, Chaput Y, deMontigny C (1988) Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Arch Pharmacol 337:246–254
Byerley WF, McConnell EJ, McCabe RT, Dawson TM, Grosser BI, Wamsley JK (1988) Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology 94:141–143
Cowen P, Fraser S, Grahame-Smith D, Greer A, Stanford C (1983) The effect of chronic antidepressant administration on beta-adrenoceptor function of the beta-adrenoceptor of the rat pineal. Br J Pharmacol 78:89–96
deMontigny C, Aghajanian GK (1978) Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202:1303–1306
Dilsaver S, Davidson R (1987) Fluoxetine subsensitizes a nicotinic mechanism involved in the regulation of core temperature. Life Sci 41:1165–1169
Dumbrille-Ross A, Tang SW (1983) Manipulations of synaptic serotonin: discrepancy of effects on sero-tonin S1 and S2 sites. Life Sci 32:2677–2684
Fowler CJ, Magnusson O, Svante BR (1984) Intra- and extraneuronal monoamine oxidase. Blood Vessels 21:126–131
Fuxe K, Ogren S, Agnoti L, Benfenati F, Fredholm B, Andersson K, Zini I, Eneroth P (1983) Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 22:389–400
Heninger GR, Charney DS (1987) Mechanism of action of antidepressant treatment: implications for the etiology and treatment of depressive disorders. In: Meltzer H (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 535–544
Hrdina P (1987) Regulation of high- and low-affinity [3H] imipramine recognition sites in rat brain by chronic treatment with antidepressants. Eur J Pharmacol 138:159–168
Hwang E, VanWoert M (1980) Acute versus chronic effects of serotonin uptake blockers on potentiation of the serotonin syndrome. Commun Psychopharmacol 4:161–176
Hwang E, Magnussen J, VanWoert M (1980) Effects of chronic fluoxetine administration on serotonin metabolism. Res Commun Chem Pathol Pharmacol 29:79–98
Jonzon B, Fredholm B (1984) Adenosine mechanisms are not affected by antidepressant concentrations of desipramine. J Pharm Pharmacol 36:846–848
Lloyd KG, Thuret F, Pilc A (1985) Upregulation of ?-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 235:191–198
Maggi A, U'Prichard DC, Enna SJ (1980) Differential effects of antidepressant treatment on brain mono-aminergic receptors. Eur J Pharmacol 61:91–98
Maj J, Mogilnicka E, Klimek V, Kordecka-Magiera A (1981) Chronic treatment with antidepressants: potentiation of clonidine-induced aggression in mice via noradrenergic mechanism. J Neural Transm 52:189–197
Mason S, Angel A (1984) Chronic and acute administration of typical and atypical antidepressants on activity of brain noradrenaline systems in the rat thiopentone anesthesia model. Psychopharmacology 84:304–309
Menkes D, Aghajanian G, McCall R (1980) Chronic antidepressant treatment enhances alpha-adrenergic and serotonergic responses in the facial nucleus. Life Sci 27:45–55
Mishra R, Sulser F (1978) Role of serotonin reuptake inhibition in the development of subsensitivity of the norepinephrine (NE) receptor coupled adenylate cyclase system. Commun Psychopharmacol 2:365–369
Mishra R, Janowsky A, Sulser F (1979) Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in brain: effects of nisoxetine versus fluoxetine. Eur J Pharmacol 60:379–382
Mishra R, Leith N, Steranka L, Sulser F (1981) The noradrenalin receptor coupled adrenylate cyclase system in brain: lack of modification by changes in availability of serotonin. Arch Pharm 316:218–224
Oreland L, Arai Y, Stenström A (1984) Age, neuro-psychiatric diseases and brain monoamine oxidase. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 291–300
Peroutka S (1987) Serotonin receptors. In: Meltzer H (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 303–312
Peroutka SJ, Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol-labeled sero-tonin receptor binding. Science 210:88–90
Pilc A (1987) The role of alpha2-adrenoceptors in the mechanism of action of antidepressant drugs. Pol J Pharmacol Pharm 39:691–713
Pilc A, Enna S (1986) Antidepressant administration has a differential effect on rat brain alpha2-adrenoceptor sensitivity to agonists and antagonists. Eur J Pharmacol 132:277–282
Reinhard JF Jr, Wurtman RJ (1977) Relation between brain 5-HIAA levels and the release of serotonin into brain synapses. Life Sci 21:1741–1746
Richelson E, Nelson A (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230:94–102
Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–286
Ross SB (1987) Distribution of the two forms of monoamine oxidase within monoaminergic neurons of the guinea pig brain. J Neurochem 48:609–614
Savage D, Frazer A, Mendels J (1979) Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on3H-serotonin receptor binding in rat brain. Eur J Pharmacol 58:87–88
Savage D, Mendels J, Frazer A (1980) Monoamine oxidase inhibitors and serotonin uptake inhibitors: differential effects on [3H]-serotonin binding sites in rat brain. J Pharmacol Exp Ther 212:259–263
Schmidt MJ, Thornberry JF (1977) Norepinephrine-stimulated cyclic AMP accumulation in brain slices in vitro after serotonin depletion or chronic administration of selective amine reuptake inhibitors. Arch Int Pharmacodyn 229:42–51
Snyder SH, Peroutka SJ (1982) A possible role of serotonin receptors in antidepressant drug action. Pharmacopsychiatry 15:131–134
Spyraki C, Fibiger H (1981) Behavioral evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74:195–206.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.